

Peer review comments – Ivermectin update

Managing COVID-19 rapid guideline (NG191)

Peer review organisations

For a list of stakeholders invited to comment on COVID-19 guidance as part of the targeted peer review, please see the [targeted peer review stakeholder list](#) on the NICE website.

Overarching category	Guideline section	Theme of comments	Action taken
General comments	Recommendation	All of the peer-reviewers agreed with the recommendation, rationale and evidence to decision. Majority of the reviewers did not have further comments.	None
Population	Evidence to decision – Equity section	One of the peer-reviewers pointed out that use of ivermectin in pregnancy should be mentioned explicitly regardless of the lack of evidence in pregnant women. Given that the BNF advises against the use of ivermectin in pregnancy	Addressed. Despite the lack of evidence on use of ivermectin in pregnant women, it has been added in the 'evidence to decision – other considerations' that BNF advises against the use of ivermectin in pregnancy.
General Comment	Recommendation	Pharmacological properties of Ivermectin – effective dose for antiviral activity: A peer-reviewer raised concerns about the in-vitro efficacy of ivermectin against SARS-CoV-2 infection.	None. The point raised was related to pharmacological properties of ivermectin and its related effectiveness in presence of monoclonal antibodies (mAb)

Date of completion: 24/05/2022

Overarching category	Guideline section	Theme of comments	Action taken
			<p>and other antivirals in in-vitro studies.</p> <p>We have not searched for evidence on the pharmacological effect of ivermectin. Therefore, no action has been taken in response to this comment.</p>